Y-Mabs Therapeutics Inc

NASDAQ:YMAB  
11.64
+0.66 (+6.01%)
Other Pre-Announcement

Y-mAbs Therapeutics Q1 Loss Per Share $0.64

Published: 05/09/2022 21:23 GMT
Y-Mabs Therapeutics Inc (YMAB) - Y-mabs Announces First Quarter Financial Results and Recent Corporate Developments.
Q1 Loss per Share $0.64.
Q1 Revenue Rose 94 Percent to $10.5 Million.
Q1 Earnings per Share View $-0.72, Revenue View $10.9 Million -- Refinitiv Ibes Data (analyst estimates).
Strong Cash Position With $156.7 Million As of March 31, 2022, Providing Runway Through Mid-2024.
Issues 2022 Full-year Danyelza Revenue Guidance of $45-$50 Million.